News
New Sementis CEO to Advance Vaccine Technology
September 2023 Biotechnology company Sementis will advance its position at the forefront of vaccine technology with the...
November 2018
UK group Enesi Pharma has signed a deal with Australian biotech Sementis to develop solid dose versions of the latter’s lead peanut hypoallergy vaccine and its chikungunya/Zika vaccine candidates.
Read more from the PharmaTimes here.
News
September 2023 Biotechnology company Sementis will advance its position at the forefront of vaccine technology with the...
News
January 2023 Sementis has exciting news. We’re pleased to announce that we’ve been awarded a $3 million Federal...
News
December 2022 Sementis are grateful and proud to have the support of DMTC Ltd to advance research and development...